期刊文献+

免疫抑制剂和辛伐他汀对血管内皮细胞增殖及其分泌内皮素的影响 被引量:3

Effects of three immunosuppressive agents and simvastatin on cell-proliferation and endothelin secretion of human endothelial cells
原文传递
导出
摘要 目的研究环磷酰胺、沙立度胺、白芍总苷、辛伐他汀对体外培养的血管内皮细胞(EC)增殖及其分泌内皮素(ET)-1的影响。方法培养EA.hy926细胞,用四氮唑蓝染色法(MTT)观察环磷酰胺(2000、500、150、50μmol/L)、沙立度胺(50、10、1、0.1、0.01μmol/L)、白芍总苷(36、18、4.5、0.5μg/ml)、辛伐他汀(10、5、2、1μmol/L)在不同浓度和不同培养时间下对EC增殖的影响;ELISA检测环磷酰胺(2000、500、150、50μmol/L)、沙立度胺(50、10、1、0.1、0.01μmol/L)、白芍总苷(36、18、4.5、0.5μg/m1)、辛伐他汀(10、5、2、1μmol/L)作用后EA.hy926细胞培养上清中ET-1水平的变化。结果(1)环磷酰胺、白芍总苷对EC增殖的抑制作用随时间的延长而增加,在作用72h时呈浓度依赖性;沙立度胺对EC的增殖无明显作用,且随时间的延长变化不大;辛伐他汀在作用24h时对EC的增殖有促进作用,随作用时间的延长对EC的增殖呈抑制作用。(2)环磷酰胺(1000、150、50μmol/L)、沙立度胺(10μmol/L)、辛伐他汀(10、5μmol/L)作用24h可显著抑制EC分泌ET-1,白芍总苷(36μg/ml)可显著促进EC分泌ET-1。结论环磷酰胺、白芍总苷、辛伐他汀对EC的增殖有明显的抑制作用;辛伐他汀能明显抑制EC分泌ET-1,环磷酰胺可抑制EC分泌ET-1。 Objective To evaluate the effects of four agents including cyclophosphomide, thalidomide ,total glucosides of peony (TGP) and simvastatin on cell-proliferation and endothlin-1 secretion of human endothelial cells (ECs). Methods EA. hy926 cells were cultured until confluence was achieved, then incubated separately for 24 h, 48 h and 72 h with various concentration of these four agents. The proliferation of ECs was detected with 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium-bromide (MTT). The amount of endothlin-1 in supernatants of ECs was determined with enzyme linked immunosorbent assay. Results ( 1 ) Cyclophosphomide, TGP and simvastatin inhibited ECs proliferation in a dose dependent manner at 72 h ( P 〈 0. 05 ). ( 2 ) Cyclophosphomide ( 50-2000 μmol/L) and simvastatin (5-10 μmol/L) decreased endothlin-1 secretion but not in dose dependent manner. Conclusion Cyclophosphomide, TGP and simvastatin can inhibit ECs proliferation. Cyclophosphomide and simvastatin can decrease endothlin-1 secretion of human ECs.
出处 《中华内科杂志》 CAS CSCD 北大核心 2008年第6期495-498,共4页 Chinese Journal of Internal Medicine
基金 国家科技支撑计划“十一五”重大项目课题(2006BA101A07)
关键词 免疫抑制剂 辛伐他汀 内皮缩血管肽类 内皮细胞 Immunosuppressive agents Simvastatin Endothelins Endothelial cells
  • 相关文献

参考文献13

  • 1陈晓,曾小峰.结缔组织病并发肺动脉高压研究新进展[J].北京医学,2006,28(5):299-301. 被引量:3
  • 2Tanaka E, Harigai M, Tanaka M,et al. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol,2002, 29 : 282-287. 被引量:1
  • 3Karmochkine M, Wechsler B, Godeau P, et al. Improvement of severe pulmonary hypertension in a patient with SLE. Ann Rheum Dis, 1996,55:561-562. 被引量:1
  • 4Lynch JP3rd, Hunninghake GW. Pulmonary complications of collagen vascular disease. Annu Rev Med, 1992,43 : 17-35. 被引量:1
  • 5Yoshio T, Masuyama J, Sumiya M, et al. Antiendothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus. J Rheumatol, 1994,21:2058-2063. 被引量:1
  • 6Shen JY, Chen SL, Wu YX, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int, 1999,18 : 147-151. 被引量:1
  • 7Hamano Y, Sugimoto H, Soubasakos MA,et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res ,2004,64 : 1570-1574. 被引量:1
  • 8Negi VS, Tripathy NK, Misra R, et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol, 1998,25:462-466. 被引量:1
  • 9Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest, 1998,101 : 2711-2719. 被引量:1
  • 10Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 2006,291 : L668-L676. 被引量:1

二级参考文献23

  • 1Denton CP,Cailes JB,Phillips GD,et al.Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis.Br J Rheumatol,1997,36:239-243. 被引量:1
  • 2Magliano M,Isenberg DA,Hillson J.Pulmonary hypertension in autoimmune rheumatic diseases:where are we now? Arthritis & Rheum,2002,46:1997-2009. 被引量:1
  • 3McGregor AJ,Canavan R,Knight C,et al.Pulmonary hypertension in systemic sclerosis:risk factors for progression and consequences for survival.Rheumatology(Oxford),2001,40:453-459. 被引量:1
  • 4Stupi AM,Steen VD,Owens GR,et al.Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.Arthritis Rheum,1986,29:515-524. 被引量:1
  • 5Koh ET,Lee P,Gladman DD,et al.Pulmonary hypertension in systemic sclerosis:an analysis of 17 patients.Br J Rheumatol,1996,35:989-993. 被引量:1
  • 6Muker JD.Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension:application of a registry approach.Ann Rheum Dis,2003,62:1088-1093. 被引量:1
  • 7Steen V,Medsger TA.Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.Arthritis Rheum,2003,48:516-522. 被引量:1
  • 8Shen JY,Chen SL,Wu YX,et al.Pulmonary hypertension in systemic lupus erythematosus.Rheumatol Int,1999,18:147-151. 被引量:1
  • 9Li EK,Tam LS.Pulmonary hypertension in systemic lupus erythematosus:clinical associations and survival in 18 patients.J Rheumatol,1999,26:1923-1929. 被引量:1
  • 10Burdt MA,Hoffman RW,Deutscher SL,et al.Long-term outcome in mixed connective tissue disease:longitudinal clinical and serologic findings.Arthritis Rheum,1999,42:899-909. 被引量:1

共引文献2

同被引文献70

引证文献3

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部